Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)
Status:
Completed
Trial end date:
2019-09-30
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, double-blind, randomized, placebo-controlled study to
evaluate the effect of iloprost on the symptomatic relief of Raynaud's Phenomenon attacks in
subjects with symptomatic Raynaud's Phenomenon secondary to Systemic Sclerosis.